TN2011000553A1 - Fgf21 mutants and uses thereof - Google Patents
Fgf21 mutants and uses thereofInfo
- Publication number
- TN2011000553A1 TN2011000553A1 TNP2011000553A TN2011000553A TN2011000553A1 TN 2011000553 A1 TN2011000553 A1 TN 2011000553A1 TN P2011000553 A TNP2011000553 A TN P2011000553A TN 2011000553 A TN2011000553 A TN 2011000553A TN 2011000553 A1 TN2011000553 A1 TN 2011000553A1
- Authority
- TN
- Tunisia
- Prior art keywords
- fgf21 mutant
- polypeptides
- fgf21 mutants
- mutant polypeptides
- pharmaceutical compositions
- Prior art date
Links
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 title abstract 4
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17573609P | 2009-05-05 | 2009-05-05 | |
| PCT/US2010/033478 WO2010129503A1 (en) | 2009-05-05 | 2010-05-04 | Fgf21 mutants and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2011000553A1 true TN2011000553A1 (en) | 2013-05-24 |
Family
ID=52988550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2011000553A TN2011000553A1 (en) | 2009-05-05 | 2011-10-31 | Fgf21 mutants and uses thereof |
Country Status (3)
| Country | Link |
|---|---|
| AR (1) | AR108568A2 (en) |
| TN (1) | TN2011000553A1 (en) |
| UA (1) | UA107458C2 (en) |
-
2010
- 2010-05-04 UA UAA201114397A patent/UA107458C2/en unknown
-
2011
- 2011-10-31 TN TNP2011000553A patent/TN2011000553A1/en unknown
-
2017
- 2017-05-18 AR ARP170101344A patent/AR108568A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA107458C2 (en) | 2015-01-12 |
| AR108568A2 (en) | 2018-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502433A1 (en) | Fgf21 mutants and uses thereof | |
| MY152721A (en) | Fgf21 mutants and uses thereof | |
| TN2011000161A1 (en) | Fgf21 mutants and uses thereof | |
| WO2010129600A3 (en) | Fgf21 mutants and uses thereof | |
| MX2011013903A (en) | Chimeric fgf19 polypeptides and uses thereof. | |
| MX2009002816A (en) | Albumin fusion proteins. | |
| PH12013501101A1 (en) | Immunosuppressive polypeptides and nucleic acids | |
| MX340807B (en) | Novel compositions for preventing and/or treating degenerative disorders of the central nervous system. | |
| AP2011005814A0 (en) | Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases. | |
| TN2011000553A1 (en) | Fgf21 mutants and uses thereof | |
| UA102395C2 (en) | Fgf21 mutants and use thereof | |
| TN2010000563A1 (en) | Fgf 21 mutants and uses thereof | |
| WO2008033374A3 (en) | Ocl-2a3 compositions and uses thereof | |
| EP2582379A4 (en) | Compositions and methods for the treatment of atherosclerosis |